4 Healthcare Stock Stories for Your Medical Portfolio Wellness
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS): Closing price $36.27
On Thursday, Isis said that follow-up preliminary data from a single dose, open-label Phase 1 study of ISIS-SMN in children suffering from spinal muscular atrophy, show that the majority of SMA children receiving the two highest doses of the drug (6 mg and 9 mg) continued to show improvements in muscle function tests as long as 14 months following a single injection of the drug. The Phase 1 data, including these preliminary follow-on data, will be presented at the International Congress of the World Muscle Society by Dr. Kathy Swoboda on October 3. Spinal muscular atrophy is a severe and rare genetic neuromuscular disease described by muscle atrophy and weakness and is the most common genetic cause of infant mortality.